$256 Million is the total value of CHI Advisors LLC's 19 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ORTX | Sell | ORCHARD THERAPEUTICS PLCads | $17,587,000 | -21.2% | 2,931,185 | -1.0% | 6.86% | -86.9% |
OVID | Sell | OVID THERAPEUTICS INC | $4,011,000 | +62.5% | 544,281 | -34.3% | 1.56% | -73.1% |
KZR | Sell | KEZAR LIFE SCIENCES INC | $1,766,000 | -11.7% | 340,973 | -25.7% | 0.69% | -85.4% |
MYOK | Sell | MYOKARDIA INC | $1,304,000 | +85.5% | 13,500 | -10.0% | 0.51% | -69.3% |
LVGO | Sell | LIVONGO HEALTH INC | $1,128,000 | -56.1% | 15,000 | -83.3% | 0.44% | -92.7% |
ADVM | Sell | ADVERUM BIOTECHNOLOGIES INC | $1,044,000 | +67.6% | 50,000 | -21.6% | 0.41% | -72.3% |
RARE | Sell | ULTRAGENYX PHARMACEUTICAL IN | $1,017,000 | -41.9% | 13,000 | -67.0% | 0.40% | -90.4% |
BPMC | Sell | BLUEPRINT MEDICINES CORP | $936,000 | -55.5% | 12,000 | -66.7% | 0.36% | -92.6% |
GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $821,000 | +2.0% | 13,000 | -17.5% | 0.32% | -83.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-08-17
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2023-11-13 |
13F-HR/A | 2023-08-22 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-11 |
SC 13G/A | 2023-02-13 |
SC 13G/A | 2023-02-13 |
SC 13G/A | 2023-02-13 |
SC 13G/A | 2023-02-13 |
SC 13G/A | 2023-02-13 |
SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.